{
    "clinical_study": {
        "@rank": "58777", 
        "arm_group": [
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Adverse Event Management Paradigms"
            }, 
            {
                "arm_group_label": "ATX-101", 
                "arm_group_type": "Active Comparator", 
                "description": "Adverse Event Management Paradigms"
            }
        ], 
        "brief_summary": {
            "textblock": "The objectives of this study are to determine the safety of ATX-101 subcutaneous (SC)\n      injections in the submental area and to evaluate the effects of four interventions, relative\n      to placebo in the submental area, particularly with regard to assessment and management of\n      pain, bruising, and swelling/edema."
        }, 
        "brief_title": "Patient Experience Study", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Pain Measurement", 
        "detailed_description": {
            "textblock": "This is to evaluate the effects of four interventions, pre- and post-SC injections of ATX\n      101 relative to placebo in approximately 80 subjects.  Subjects will be randomized to either\n      ATX-101 or placebo at a ratio of 4:1.  Approximately 64 subjects will receive ATX 101 and\n      approximately 16 subjects will receive placebo in one of four Patient Experience Management\n      Paradigms.\n\n      Subjects are required to visit the research facility on 10 separate occasions for\n      protocol-defined treatments, procedures, tests, and observations."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Sufficient volume of submental fat graded by the investigator\n\n          2. Dissatisfaction with the submental area expressed by the subject a\n\n          3. Males and nonpregnant, nonlactating females 18 to 65 years of age\n\n          4. History of stable body weight for at least 6 months and body mass index (BMI) of \u226440\n             kg/m2.\n\n          5. Acceptable skin laxity as determined by the investigator\n\n          6. Agreement by the subject to refrain from making significant changes, in the\n             documented judgment of the investigator, to his or her dietary or exercise habits\n             during the course of the subject's participation.\n\n          7. Agreement to forego any treatment or behavior (e.g., unshaven facial hair)\n\n          8. Signed informed consent obtained before any study-specific procedure is performed.\n\n        Exclusion Criteria:\n\n          1. No prior intervention for SMF or recent cosmetic procedure in the neck or chin area\n\n          2. Absence of clinically significant health problems\n\n          3. Body mass index >40.0 kg/m2 as determined prior to randomization.\n\n          4. History of drug or alcohol abuse."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "80", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 30, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02007434", 
            "org_study_id": "ATX-101-13-36"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Placebo", 
                    "ATX-101"
                ], 
                "description": "cold", 
                "intervention_name": "Thermal", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": [
                    "Placebo", 
                    "ATX-101"
                ], 
                "description": "analgesics/anesthetics/antihistamines", 
                "intervention_name": "Pharmaceutical", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Placebo", 
                    "ATX-101"
                ], 
                "description": "compression", 
                "intervention_name": "Mechanical", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "April 17, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Temple", 
                    "country": "United States", 
                    "state": "Arizona", 
                    "zip": "85283"
                }, 
                "name": "Celerion"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Single Center, Double-blind, Parallel-group, Two Factor Patient Experience Management Study of ATX-101 (Deoxycholic Acid Injection) for the Reduction of Localized Subcutaneous Fat in the Submental Area", 
        "overall_official": {
            "affiliation": "Sponsor GmbH", 
            "last_name": "Frederick Beddingfield, III, MD, PhD", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Pain assessment using VAS", 
                "safety_issue": "No", 
                "time_frame": "84 days"
            }, 
            {
                "measure": "Pain assessment using McGill Pain Questionnaire", 
                "safety_issue": "No", 
                "time_frame": "84 days"
            }, 
            {
                "measure": "Categorical assessment of swelling", 
                "safety_issue": "No", 
                "time_frame": "84 days"
            }, 
            {
                "measure": "Categorical assessment of bruising", 
                "safety_issue": "No", 
                "time_frame": "84 days"
            }, 
            {
                "measure": "Categorical assessment of induration", 
                "safety_issue": "No", 
                "time_frame": "84 days"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02007434"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Efficacy assessments using a clinician rating scale", 
                "safety_issue": "No", 
                "time_frame": "84 days"
            }, 
            {
                "measure": "Efficacy assessments using a patient reported rating scale", 
                "safety_issue": "No", 
                "time_frame": "84 days"
            }, 
            {
                "measure": "Efficacy assessments using the subject self rating scale", 
                "safety_issue": "No", 
                "time_frame": "84 days"
            }, 
            {
                "measure": "Efficacy assessments using submental skin laxity grade", 
                "safety_issue": "No", 
                "time_frame": "84 days"
            }, 
            {
                "measure": "Efficacy assessments on submental fat using calipers", 
                "safety_issue": "No", 
                "time_frame": "84 days"
            }
        ], 
        "source": "Kythera Biopharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Kythera Biopharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}